Movalis efficacy and safety in the treatment of locomotor apparatus diseases
Movalis efficacy and safety in the treatment of locomotor apparatus diseases
Treatment of chronic locomotor diseases is a complex task. Antiinflammatory and analgesic therapy are complicated by advanced age, concomitant diseases and necessity of its treatment. Frequently used classic nonsteroidal antiinflammatory drugs besides positive effects often cause adverse effects from gastrointestinal tract, liver, kidneys, bronchus, what limits the providing of adequate therapy. The cyclo-oxygenase-2 selective inhibitors meloxicam (Movalis) have the same effectiveness as classic nonsteroidal antiinflammatory drugs, but much better tolerability, including elderly people. The paper includes the results of research and clinical practice, confirming the efficiency and safety of Movalis.

Keywords: cyclo-oxygenase-2 selective inhibitors, nonsteroidal antiinflammatory drugs, antiinflammatory therapy, rheumatic diseases, meloxicam, adverse events